If the use of the right treatment at the right time might 'cure' juvenile idiopathic arthritis, how do we determine the optimum timing of biologic therapy? The use of standardized consensus treatment plans in comparative effectiveness trials and of early testing for responsiveness to biologic treatment could lead the way.
